Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04915937 · ClinicalTrials.gov registry record · NA
Formula Tolerance of Term Infants
A NA study, sponsored by Abbott Nutrition.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT04915937: Completed NA study, sponsored by Abbott Nutrition.
NCT04915937 is a NA study that has completed, run by Abbott Nutrition. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04915937, a NA study, has completed, sponsored by Abbott Nutrition.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants
Primary Outcome
Absolute and % change in fussiness severity reported from Daily Tolerance Diary
Interventions
- OTHER Study Infant Formula
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2021-07-13 |
| Est. Completion | 2022-11-22 |
| Phase | NA |
What the finished NCT04915937 record still lists
NCT04915937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Study Infant Formula is the first listed.
NCT04915937 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04915937 about?
NCT04915937 is a clinical study titled "Formula Tolerance of Term Infants". To assess the effects of infant formula with oligosaccharides on symptoms of formula intolerance in healthy, term infants
What is the current status of trial NCT04915937?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2021-07-13. Estimated completion is 2022-11-22.
What interventions are being tested in trial NCT04915937?
The interventions under investigation include: Study Infant Formula (OTHER).
Who is sponsoring clinical trial NCT04915937?
This trial is sponsored by Abbott Nutrition, which has 89 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04915937's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI